eLife (Aug 2021)
Endomembrane targeting of human OAS1 p46 augments antiviral activity
- Frank W Soveg,
- Johannes Schwerk,
- Nandan S Gokhale,
- Karen Cerosaletti,
- Julian R Smith,
- Erola Pairo-Castineira,
- Alison M Kell,
- Adriana Forero,
- Shivam A Zaver,
- Katharina Esser-Nobis,
- Justin A Roby,
- Tien-Ying Hsiang,
- Snehal Ozarkar,
- Jonathan M Clingan,
- Eileen T McAnarney,
- Amy EL Stone,
- Uma Malhotra,
- Cate Speake,
- Joseph Perez,
- Chiraag Balu,
- Eric J Allenspach,
- Jennifer L Hyde,
- Vineet D Menachery,
- Saumendra N Sarkar,
- Joshua J Woodward,
- Daniel B Stetson,
- John Kenneth Baillie,
- Jane H Buckner,
- Michael Gale Jr,
- Ram Savan
Affiliations
- Frank W Soveg
- ORCiD
- Department of Immunology, School of Medicine, University of Washington, Seattle, United States; Center for Innate Immunity and Immune Disease, University of Washington, Seattle, United States
- Johannes Schwerk
- ORCiD
- Department of Immunology, School of Medicine, University of Washington, Seattle, United States; Center for Innate Immunity and Immune Disease, University of Washington, Seattle, United States
- Nandan S Gokhale
- Department of Immunology, School of Medicine, University of Washington, Seattle, United States; Center for Innate Immunity and Immune Disease, University of Washington, Seattle, United States
- Karen Cerosaletti
- ORCiD
- Benaroya Research Institute at Virginia Mason, Seattle, United States
- Julian R Smith
- Department of Immunology, School of Medicine, University of Washington, Seattle, United States; Center for Innate Immunity and Immune Disease, University of Washington, Seattle, United States
- Erola Pairo-Castineira
- Roslin Institute, University of Edinburgh, Edinburgh, United Kingdom
- Alison M Kell
- Department of Immunology, School of Medicine, University of Washington, Seattle, United States; Center for Innate Immunity and Immune Disease, University of Washington, Seattle, United States; Department of Molecular Genetics and Microbiology, School of Medicine, University of New Mexico, Albuquerque, United States
- Adriana Forero
- ORCiD
- Department of Immunology, School of Medicine, University of Washington, Seattle, United States; Center for Innate Immunity and Immune Disease, University of Washington, Seattle, United States; Department of Microbial Infection and Immunity, College of Medicine, The Ohio State University, Columbus, United States
- Shivam A Zaver
- Department of Microbiology, School of Medicine, University of Washington, Seattle, United States
- Katharina Esser-Nobis
- ORCiD
- Department of Immunology, School of Medicine, University of Washington, Seattle, United States; Center for Innate Immunity and Immune Disease, University of Washington, Seattle, United States
- Justin A Roby
- Department of Immunology, School of Medicine, University of Washington, Seattle, United States; Center for Innate Immunity and Immune Disease, University of Washington, Seattle, United States
- Tien-Ying Hsiang
- Department of Immunology, School of Medicine, University of Washington, Seattle, United States; Center for Innate Immunity and Immune Disease, University of Washington, Seattle, United States
- Snehal Ozarkar
- Department of Immunology, School of Medicine, University of Washington, Seattle, United States; Center for Innate Immunity and Immune Disease, University of Washington, Seattle, United States
- Jonathan M Clingan
- ORCiD
- Department of Immunology, School of Medicine, University of Washington, Seattle, United States; Center for Innate Immunity and Immune Disease, University of Washington, Seattle, United States
- Eileen T McAnarney
- ORCiD
- Department of Microbiology and Immunology, University of Texas Medical Center, Galveston, United States
- Amy EL Stone
- ORCiD
- Department of Immunology, School of Medicine, University of Washington, Seattle, United States; Center for Innate Immunity and Immune Disease, University of Washington, Seattle, United States; Department of Basic Sciences, College of Osteopathic Medicine, Touro University Nevada, Henderson, United States
- Uma Malhotra
- Department of Infectious Disease, Virginia Mason Medical Center, Seattle, United States; Department of Medicine, Section of Infectious Diseases, University of Washington, Seattle, United States
- Cate Speake
- ORCiD
- Benaroya Research Institute at Virginia Mason, Seattle, United States
- Joseph Perez
- Cancer Virology Program, University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, United States
- Chiraag Balu
- Department of Immunology, School of Medicine, University of Washington, Seattle, United States; Center for Innate Immunity and Immune Disease, University of Washington, Seattle, United States
- Eric J Allenspach
- ORCiD
- Center for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, United States
- Jennifer L Hyde
- ORCiD
- Department of Microbial Infection and Immunity, College of Medicine, The Ohio State University, Columbus, United States
- Vineet D Menachery
- Department of Microbiology and Immunology, University of Texas Medical Center, Galveston, United States
- Saumendra N Sarkar
- ORCiD
- Cancer Virology Program, University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, United States
- Joshua J Woodward
- ORCiD
- Center for Innate Immunity and Immune Disease, University of Washington, Seattle, United States; Department of Microbiology, School of Medicine, University of Washington, Seattle, United States
- Daniel B Stetson
- ORCiD
- Department of Immunology, School of Medicine, University of Washington, Seattle, United States; Center for Innate Immunity and Immune Disease, University of Washington, Seattle, United States
- John Kenneth Baillie
- ORCiD
- Roslin Institute, University of Edinburgh, Edinburgh, United Kingdom; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Edinburgh, United Kingdom
- Jane H Buckner
- Benaroya Research Institute at Virginia Mason, Seattle, United States
- Michael Gale Jr
- Department of Immunology, School of Medicine, University of Washington, Seattle, United States; Center for Innate Immunity and Immune Disease, University of Washington, Seattle, United States
- Ram Savan
- ORCiD
- Department of Immunology, School of Medicine, University of Washington, Seattle, United States; Center for Innate Immunity and Immune Disease, University of Washington, Seattle, United States
- DOI
- https://doi.org/10.7554/eLife.71047
- Journal volume & issue
-
Vol. 10
Abstract
Many host RNA sensors are positioned in the cytosol to detect viral RNA during infection. However, most positive-strand RNA viruses replicate within a modified organelle co-opted from intracellular membranes of the endomembrane system, which shields viral products from cellular innate immune sensors. Targeting innate RNA sensors to the endomembrane system may enhance their ability to sense RNA generated by viruses that use these compartments for replication. Here, we reveal that an isoform of oligoadenylate synthetase 1, OAS1 p46, is prenylated and targeted to the endomembrane system. Membrane localization of OAS1 p46 confers enhanced access to viral replication sites and results in increased antiviral activity against a subset of RNA viruses including flaviviruses, picornaviruses, and SARS-CoV-2. Finally, our human genetic analysis shows that the OAS1 splice-site SNP responsible for production of the OAS1 p46 isoform correlates with protection from severe COVID-19. This study highlights the importance of endomembrane targeting for the antiviral specificity of OAS1 and suggests that early control of SARS-CoV-2 replication through OAS1 p46 is an important determinant of COVID-19 severity.
Keywords